Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bidirectional ePIPAC-oxaliplatin plus systemic chemotherapy for unresectable colorectal peritoneal metastases
NL-OMON50015Phase 2Completed
- Sponsor
- Catharina Ziekenhuis
- Start
- Feb 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in colorectal cancer (CRC), Appendiceal carcinoma and peritoneal carcinomatosis (PC), sponsored by Catharina Ziekenhuis. Primary endpoint: Major toxicity. Started Feb 2020; status: completed.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)Appendiceal carcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NL-OMON50015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50015.